These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 26227906)

  • 21. TFP5, a Peptide Inhibitor of Aberrant and Hyperactive Cdk5/p25, Attenuates Pathological Phenotypes and Restores Synaptic Function in CK-p25Tg Mice.
    Shukla V; Seo J; Binukumar BK; Amin ND; Reddy P; Grant P; Kuntz S; Kesavapany S; Steiner J; Mishra SK; Tsai LH; Pant HC
    J Alzheimers Dis; 2017; 56(1):335-349. PubMed ID: 28085018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of Cdk5-mediated Drp1 phosphorylation in Aβ
    Guo MY; Shang L; Hu YY; Jiang LP; Wan YY; Zhou QQ; Zhang K; Liao HF; Yi JL; Han XJ
    J Cell Biochem; 2018 Jun; 119(6):4815-4825. PubMed ID: 29345339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. S-nitrosylation of Cdk5: potential implications in amyloid-β-related neurotoxicity in Alzheimer disease.
    Qu J; Nakamura T; Holland EA; McKercher SR; Lipton SA
    Prion; 2012; 6(4):364-70. PubMed ID: 22874667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent evidence regarding a role for Cdk5 dysregulation in Alzheimer's disease.
    Monaco EA
    Curr Alzheimer Res; 2004 Feb; 1(1):33-8. PubMed ID: 15975083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclin-dependent kinase 5 activator p35 over-expression and amyloid beta synergism increase apoptosis in cultured neuronal cells.
    Utreras E; Maccioni R; González-Billault C
    Neuroscience; 2009 Jul; 161(4):978-87. PubMed ID: 19362124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cdk5-p25 as a key element linking amyloid and tau pathologies in Alzheimer's disease: Mechanisms and possible therapeutic interventions.
    Maitra S; Vincent B
    Life Sci; 2022 Nov; 308():120986. PubMed ID: 36152679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CDK5 as a therapeutic tool for the treatment of Alzheimer's disease: A review.
    Garemilla S; Kumari R; Kumar R
    Eur J Pharmacol; 2024 Sep; 978():176760. PubMed ID: 38901526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease.
    Imahori K; Uchida T
    J Biochem; 1997 Feb; 121(2):179-88. PubMed ID: 9089387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Olfactory Deprivation Hastens Alzheimer-Like Pathologies in a Human Tau-Overexpressed Mouse Model via Activation of cdk5.
    Li K; Liu FF; He CX; Huang HZ; Xie AJ; Hu F; Liu D; Wang JZ; Zhu LQ
    Mol Neurobiol; 2016 Jan; 53(1):391-401. PubMed ID: 25465240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cdk5-Foxo3 axis: initially neuroprotective, eventually neurodegenerative in Alzheimer's disease models.
    Shi C; Viccaro K; Lee HG; Shah K
    J Cell Sci; 2016 May; 129(9):1815-1830. PubMed ID: 28157684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Roles of cyclin-dependent kinase 5 in central nervous system development and neurodegenerative diseases].
    Chen J; Wang ZF
    Sheng Li Xue Bao; 2010 Aug; 62(4):295-308. PubMed ID: 20717630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glutathione-S-transferase P1 is a critical regulator of Cdk5 kinase activity.
    Sun KH; Chang KH; Clawson S; Ghosh S; Mirzaei H; Regnier F; Shah K
    J Neurochem; 2011 Sep; 118(5):902-14. PubMed ID: 21668448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5.
    Kesavapany S; Zheng YL; Amin N; Pant HC
    Biotechnol J; 2007 Aug; 2(8):978-87. PubMed ID: 17526058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Melatonin in Alzheimer's Disease: A Latent Endogenous Regulator of Neurogenesis to Mitigate Alzheimer's Neuropathology.
    Hossain MF; Uddin MS; Uddin GMS; Sumsuzzman DM; Islam MS; Barreto GE; Mathew B; Ashraf GM
    Mol Neurobiol; 2019 Dec; 56(12):8255-8276. PubMed ID: 31209782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cdk5 as a drug target for the treatment of Alzheimer's disease.
    Lau LF; Seymour PA; Sanner MA; Schachter JB
    J Mol Neurosci; 2002 Dec; 19(3):267-73. PubMed ID: 12540052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impaired autophagy and APP processing in Alzheimer's disease: The potential role of Beclin 1 interactome.
    Salminen A; Kaarniranta K; Kauppinen A; Ojala J; Haapasalo A; Soininen H; Hiltunen M
    Prog Neurobiol; 2013; 106-107():33-54. PubMed ID: 23827971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cdk5 activity in the brain - multiple paths of regulation.
    Shah K; Lahiri DK
    J Cell Sci; 2014 Jun; 127(Pt 11):2391-400. PubMed ID: 24879856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of protein kinases in neurodegenerative disease: cyclin-dependent kinases in Alzheimer's disease.
    Monaco EA; Vallano ML
    Front Biosci; 2005 Jan; 10():143-59. PubMed ID: 15574357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of Early Growth Response 1 in the Hippocampus Alleviates Neuropathology and Improves Cognition in an Alzheimer Model with Plaques and Tangles.
    Qin X; Wang Y; Paudel HK
    Am J Pathol; 2017 Aug; 187(8):1828-1847. PubMed ID: 28641077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.